期刊文献+

2011年药品安全信息回顾 被引量:1

下载PDF
导出
摘要 本文选录美国食品药品监督管理局(FDA)、欧洲药品管理局(EMA)、加拿大卫生部、英国药品和健康产品管理局(MHRA)、澳大利亚治疗产品局(TGA)、法国卫生安全和健康产品委员会(AFSSAPS)以及我国药物评价中心网2011年发布的部分药品安全信息,包括药品退市、安全评估、安全警告、修改药品说明书等信息。
作者 黄洁 阳国平
出处 《中南药学》 CAS 2012年第11期863-869,共7页 Central South Pharmacy
  • 相关文献

参考文献58

  • 1European Medicines Agency recommends suspension of oral buflomedil-containing medicines [EB/OL].[2010-05-20]. http: //www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/05/WC500106555. pdf.
  • 2Garcia Rodriguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs [J]. Br J Clin Pharmacol, 1999, 48( 6 ): 847-852.
  • 3Murkin JM. Lessons learned in antifibrinolytic therapy: The BART trial. Semin Cardiothorac Vasc Anesth [J]. 2009, 13 ( 2 ) : 127-131.
  • 4European Medicines Agency completes its review of Avastin used in breast cancer treatment [EB/OL].[2010-12-16]. http: //www.ema. europa.eu/docs/en_GB/document_library/Press_release/2010/12/ WC500099929. pdf.
  • 5Cervarix ( HPV vaccine ) : Update on UK safety covering the first two years of the HPV immunisation programme [EB/OL]. [2011-3-17].http: //www.mhra.gov.uk/home/groups/pl-p/ documcon096797. pdf.
  • 6Xiao Ding, Eugenio Andraca-Carrera, Charles Cooper, et al. No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis [EB/OL]. [2011-03-01]. http: //www. retroconference.org/2011/PDFs/808.pdf.
  • 7Opinion following an article 30 referral for Singulair and associated names [EB/OL].[2008-7-11 ].http : //www.ema.europa.eu/ docs/en_GB/document library/Referrals_document/Singulair-30/ WC500008945.pdf.
  • 8European Medicines Agency concludes review of systemic nimesulide-containing medicines [EB/OL]. [2011-06-23].http: //www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/06/WC500107903.pdf.
  • 9European Medicines Agency concludes that benefit-risk balance of Revlimid remains positive [EB/OL]. [2011-09-23].http: // www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/09/WC500112827.pdf.
  • 10FDA Drug Safety Communication: Abnormal heart rhythms associated with use ofAnzemet ( dolasetron mesylate ) [EB/OL]. [2010- 12-17]. http: //www.fda.gov/Drugs/DrugSafety/ucm237081. htm#safety_announcement.

同被引文献7

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部